Abstract
The paradigm of using nanoparticulate pharmaceutical carriers has been well established over the past decade, both in pharmaceutical research and in the clinical setting. Drug carriers are expected to stay in the blood for long time, accumulate in pathological sites with affected and leaky vasculature (tumors, inflammations, and infarcted areas) via the enhanced permeability and retention (EPR) effect, and facilitate targeted delivery of specific ligand-modified drugs and drug carriers into poorly accessible areas. Among various approaches to specifically target drug-loaded carrier systems to required pathological sites in the body, two seem to be most advanced – passive (EPR effect-mediated) targeting, based on the longevity of the pharmaceutical carrier in the blood and its accumulation in pathological sites with compromised vasculature, and active targeting, based on the attachment of specific ligands to the surface of pharmaceutical carriers to recognize and bind pathological cells. Here, we will consider and discuss these two targeting approaches using tumor targeting as an example.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abra RM, Bankert RB, Chen F, Egilmez NK, Huang K, Saville R, Slater JL, Sugano M, Yokota SJ (2002) The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients. J Liposome Res 12:1–3
Adams ML, Lavasanifar A, Kwon GS (2003) Amphiphilic block copolymers for drug delivery. J Pharm Sci 92:1343–1355
Aliabadi HM, Lavasanifar A (2006) Polymeric micelles for drug delivery. Expert Opin Drug Deliv 3:139–162
Allen C, Yu Y, Maysinger D, Eisenberg A (1998) Polycaprolactone-b-poly(ethylene oxide) block copolymer micelles as a novel drug delivery vehicle for neurotrophic agents FK506 and L-685,818. Bioconjug Chem 9:564–572
Allen TM (1994) The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system. Adv Drug Deliv Rev 13:285–309
Allen TM, Brandeis E, Hansen CB, Kao GY, Zalipsky S (1995a) A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta 1237:99–108
Allen TM, Hansen C (1991) Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta 1068:133–141
Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A (1991) Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066:29–36
Allen TM, Hansen C, Rutledge J (1989) Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta 981:27–35
Allen TM, Hansen CB, de Menezes DEL (1995b) Pharmacokinetics of long-circulating liposomes. Adv Drug Deliv Rev 16:267–284
Allen TM, Mehra T, Hansen C, Chin YC (1992) Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine. Cancer Res 52:2431–2439
Allen TM, Mumbengegwi DR, Charrois GJ (2005) Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res 11:3567–3573
Alonso MJ (2004) Nanomedicines for overcoming biological barriers. Biomed Pharmacother 58:168–172
Asai T, Shimizu K, Kondo M, Kuromi K, Watanabe K, Ogino K, Taki T, Shuto S, Matsuda A, Oku N (2002) Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels. FEBS Lett 520:167–170
Asgeirsdottir SA, Zwiers PJ, Morselt HW, Moorlag HE, Bakker HI, Heeringa P, Kok JW, Kallenberg CG, Molema G, Kamps JA (2008) Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded AbEsel liposomes. Am J Physiol Renal Physiol 294:F554–F561
Asokan A, Cho MJ (2003) Cytosolic delivery of macromolecules II. Mechanistic studies with pH-sensitive morpholine lipids. Biochim Biophys Acta 1611:151–160
Atobe K, Ishida T, Ishida E, Hashimoto K, Kobayashi H, Yasuda J, Aoki T, Obata K, Kikuchi H, Akita H, Asai T, Harashima H, Oku N, Kiwada H (2007) In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP). Biol Pharm Bull 30:972–978
Attwood D, Florence AT (1983) Surfactant systems: their chemistry, pharmacy, and biology. Chapman and Hall, London, p 794
Bae Y, Nishiyama N, Fukushima S, Koyama H, Yasuhiro M, Kataoka K (2005) Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug Chem 16:122–130
Baum P, Muller D, Ruger R, Kontermann RE (2007) Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells. J Drug Target 15:399–406
Beduneau A, Saulnier P, Hindre F, Clavreul A, Leroux JC, Benoit JP (2007) Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab' fragments. Biomaterials 28:4978–4990
Blume G, Cevc G, Crommelin MD, Bakker-Woudenberg IA, Kluft C, Storm G (1993) Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim Biophys Acta 1149:180–184
Bogdanov AA Jr, Klibanov AL, Torchilin VP (1988) Protein immobilization on the surface of liposomes via carbodiimide activation in the presence of N-hydroxysulfosuccinimide. FEBS Lett 231:381–384
Boman NL, Masin D, Mayer LD, Cullis PR, Bally MB (1994) Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 54:2830–2833
Boomer JA, Thompson DH (1999) Synthesis of acid-labile diplasmenyl lipids for drug and gene delivery applications. Chem Phys Lipids 99:145–153
Brignole C, Marimpietri D, Gambini C, Allen TM, Ponzoni M, Pastorino F (2003) Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma. Cancer Lett 197:199–204
Budker V, Gurevich V, Hagstrom JE, Bortzov F, Wolff JA (1996) pH-sensitive, cationic liposomes: a new synthetic virus-like vector. Nat Biotechnol 14:760–764
Cammas S, Suzuki K, Sone C, Sakurai Y, Kataoka K, Okano T (1997) Thermo-responsive polymer nanoparticles with a core-shell micelle structure as site-specific drug carriers. J Control Release 48:157–164
Chazov EI, Alexeev AV, Antonov AS, Koteliansky VE, Leytin VL, Lyubimova EV, Repin VS, Sviridov DD, Torchilin VP, Smirnov VN (1981) Endothelial cell culture on fibrillar collagen: model to study platelet adhesion and liposome targeting to intercellular collagen matrix. Proc Natl Acad Sci USA 78:5603–5607
Chazov EI, Matveeva LS, Mazaev AV, Sargin KE, Sadovskaia GV, Ruda MI (1976) Intracoronary administration of fibrinolysin in acute myocardial infarct. Ter Arkh 48:8–19
Chekhonin VP, Kabanov AV, Zhirkov YA, Morozov GV (1991) Fatty acid acylated Fab-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain. FEBS Lett 287:149–152
Cheng WW, Allen TM (2008) Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J Control Release 126:50–58
Cheng WW, Das D, Suresh M, Allen TM (2007) Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells. Biochim Biophys Acta 1768:21–29
Cheung CY, Murthy N, Stayton PS, Hoffman AS (2001) A pH-sensitive polymer that enhances cationic lipid-mediated gene transfer. Bioconjug Chem 12:906–910
Chonn A, Semple SC, Cullis PR (1991) Separation of large unilamellar liposomes from blood components by a spin column procedure: towards identifying plasma proteins which mediate liposome clearance in vivo. Biochim Biophys Acta 1070:215–222
Chonn A, Semple SC, Cullis PR (1992) Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem 267:18759–18765
Chung JE, Yokoyama M, Aoyagi T, Sakurai Y, Okano T (1998) Effect of molecular architecture of hydrophobically modified poly(N-isopropylacrylamide) on the formation of thermoresponsive core-shell micellar drug carriers. J Control Release 53:119–130
Chung JE, Yokoyama M, Yamato M, Aoyagi T, Sakurai Y, Okano T (1999) Thermo-responsive drug delivery from polymeric micelles constructed using block copolymers of poly(N-isopropylacrylamide) and poly(butylmethacrylate). J Control Release 62:115–127
Cohen S, Bernstein H (1996) Microparticulate systems for the delivery of proteins and vaccines. Drugs and the pharmaceutical sciences, Vol 77. Marcel Dekker, New York, p 525
Connor J, Huang L (1986) pH-sensitive immunoliposomes as an efficient and target-specific carrier for antitumor drugs. Cancer Res 46:3431–3435
Dagar S, Krishnadas A, Rubinstein I, Blend MJ, Onyuksel H (2003) VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. J Control Release 91:123–133
Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D, Brampton M, Halbert G, Ranson M (2004) Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer 90:2085–2091
Dash PR, Read ML, Fisher KD, Howard KA, Wolfert M, Oupicky D, Subr V, Strohalm J, Ulbrich K, Seymour LW (2000) Decreased binding to proteins and cells of polymeric gene delivery vectors surface modified with a multivalent hydrophilic polymer and retargeting through attachment of transferrin. J Biol Chem 275:3793–3802
Derycke AS, De Witte PA (2002) Transferrin-mediated targeting of hypericin embedded in sterically stabilized PEG-liposomes. Int J Oncol 20:181–187
Ding L, Samuel J, MacLean GD, Noujaim AA, Diener E, Longenecker BM (1990) Effective drug-antibody targeting using a novel monoclonal antibody against the proliferative compartment of mammalian squamous carcinomas. Cancer Immunol Immunother 32:105–109
Drummond DC, Hong K, Park JW, Benz CC, Kirpotin DB (2000) Liposome targeting to tumors using vitamin and growth factor receptors. Vitam Horm 60:285–332
Dunnick JK, McDougall IR, Aragon S, Goris ML, Kriss JP (1975) Vesicle interactions with polyamino acids and antibody: in vitro and in vivo studies. J Nucl Med 16:483–487
Eavarone DA, Yu X, Bellamkonda RV (2000) Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. J Biomed Mater Res 51:10–14
Elbayoumi TA, Torchilin VP (2006) Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Eur J Nucl Med Mol Imaging 33:1196–1205
Elbayoumi TA, Torchilin VP (2007) Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Eur J Pharm Sci 32:159–168
Elbayoumi TA, Torchilin VP (2008) Tumor-specific antibody-mediated targeted delivery of Doxil® reduces the manifestation of auricular erythema side effect in mice. Int J Pharm 357:272–279
Ewer MS, Martin FJ, Henderson C, Shapiro CL, Benjamin RS, Gabizon AA (2004) Cardiac safety of liposomal anthracyclines. Semin Oncol 31:161–181
Fattal E, Couvreur P, Dubernet C (2004) “Smart” delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Adv Drug Deliv Rev 56:931–946
Flavell DJ, Noss A, Pulford KA, Ling N, Flavell SU (1997) Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice. Cancer Res 57: 4824–4829
Francis GE, Delgado C (2000) Drug targeting: strategies, principles, and applications. Humana Press, Totowa, N.J
Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54:987–992
Gabizon A, Papahadjopoulos D (1988) Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 85:6949–6953
Gabizon A, Papahadjopoulos D (1992) The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophys Acta 1103:94–100
Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S (2004) Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev 56:1177–1192
Gabizon AA (1992) Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 52:891–896
Gabizon AA (1995) Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv Drug Deliv Rev 16:285–294
Gabizon AA (2001) Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 19:424–436
Gao Z, Eisenberg AA (1993) A model of micellization for block copolymers in solution. Macromolecules 26:7353–7360
Gao Z, Lukyanov AN, Chakilam AR, Torchilin VP (2003) PEG-PE/phosphatidylcholine mixed immunomicelles specifically deliver encapsulated taxol to tumor cells of different origin and promote their efficient killing. J Drug Target 11:87–92
Gijsens A, Derycke A, Missiaen L, De Vos D, Huwyler J, Eberle A, de Witte P (2002) Targeting of the photocytotoxic compound AlPcS4 to Hela cells by transferrin conjugated PEG-liposomes. Int J Cancer 101:78–85
Goldmacher VS, Blatter WA, Lambert JM, Chari RVJ (2002) Immunotoxins and antibody-drug conjugates for cancer treatment. In: Muzykantov V, Torchilin VP (eds) Biomedical aspects of drug targeting. Kluwer, Dordrecht, pp 291–309
Goncalves A, Braud AC, Viret F, Genre D, Gravis G, Tarpin C, Giovannini M, Maraninchi D, Viens P (2003) Phase I study of pegylated liposomal doxorubicin (Caelyx) in combination with carboplatin in patients with advanced solid tumors. Anticancer Res 23:3543–3548
Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R (1994) Biodegradable long-circulating polymeric nanospheres. Science 263:1600–1603
Gregoriadis G (1977) Targeting of drugs. Nature 265:407–411
Gregoriadis G (1988) Liposomes as drug carriers: recent trends and progress. Wiley, New York, p 910
Gregoriadis G (1993) Liposome technology, 2nd edn. CRC Press, Boca Raton, FL
Gregoriadis G (2007) Liposome technology: liposome preparation and related techniques, 3rd edn, Vol 1. Taylor & Francis, London, UK, p 352
Guo X, Szoka FC Jr (2001) Steric stabilization of fusogenic liposomes by a low-pH sensitive PEG-diortho ester-lipid conjugate. Bioconjugate Chem 12:291–300
Gupta B, Torchilin VP (2007) Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol Immunother 56:1215–1223
Gupta Y, Jain A, Jain P, Jain SK (2007) Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumor cells. J Drug Target 15:231–240
Haber E (1994) Antibody targeting as a strategy in thrombolysis. In: Khaw BA, Narula J, Strauss HW (eds) Monoclonal antibodies in cardiovascular diseases. Lea & Febiger, Malvern, pp 187–197
Hafez IM, Maurer N, Cullis PR (2001) On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther 8:1188–1196
Hagan SA, Coombes AGA, Garnett MC, Dunn SE, Davies MC, Illum L, Davis SS (1996) Polylactide-poly(ethylene glycol) copolymers as drug delivery systems 1. Characterization of water dispersible micelle-forming systems. Langmuir 12:2153–2161
Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, Nakatomi I, Yokoyama M, Kataoka K, Kakizoe T (2005) NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 92:1240–1246
Harada A, Kataoka K (1998) Novel polyion complex micelles entrapping enzyme molecules in the core: preparation of narrowly-distributed micelles from lysozyme and poly(ethylene glycol)-poly(aspartic acid) block copolymer in aqueous medium. Macromolecules 31:288–294
Harrington KJ, Lewanski C, Northcote AD, Whittaker J, Peters AM, Vile RG, Stewart JS (2001) Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur J Cancer 37:2015–2022
Hashida M, Nishikawa M, Yamashita F, Takakura Y (2001) Cell-specific delivery of genes with glycosylated carriers. Adv Drug Deliv Rev 52:187–196
Hatakeyama H, Akita H, Ishida E, Hashimoto K, Kobayashi H, Aoki T, Yasuda J, Obata K, Kikuchi H, Ishida T, Kiwada H, Harashima H (2007) Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int J Pharm 342:194–200
Hatakeyama H, Akita H, Maruyama K, Suhara T, Harashima H (2004) Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. Int J Pharm 281:25–33
Heath TD, Robertson D, Birbeck MS, Davies AJ (1980) Covalent attachment of horseradish peroxidase to the outer surface of liposomes. Biochim Biophys Acta 599:42–62
Helmlinger G, Yuan F, Dellian M, Jain RK (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3:177–182
Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK (1998) Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 95:4607–4612
Hosokawa S, Tagawa T, Niki H, Hirakawa Y, Nohga K, Nagaike K (2003) Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner. Br J Cancer 89:1545–1551
Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D (1992) Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 52:6774–6781
Huang SK, Stauffer PR, Hong K, Guo JW, Phillips TL, Huang A, Papahadjopoulos D (1994) Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res 54:2186–2191
Hunter RJ (1991) Foundations of colloid science. Oxford University Press, New York
Hussain S, Pluckthun A, Allen TM, Zangemeister-Wittke U (2007) Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol Cancer Ther 6:3019–3027
Huwyler J, Wu D, Pardridge WM (1996) Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 93:14164–14169
Hwang KJ (1987) Liposome pharmacokinetics. In: Ostro MJ (ed) Liposomes: from biophysics to therapeutics. Dekker, New York, pp 109–156
Iakoubov L, Mongayt D, Torchilin VP (1995a) Monoclonal anti-nuclear autoantibody from the aged effectively suppresses tumor development in vivo. Cancer Biother Radiopharm 8:299–310
Iakoubov L, Rokhlin O, Torchilin V (1995b) Anti-nuclear autoantibodies of the aged reactive against the surface of tumor but not normal cells. Immunol Lett 47:147–149
Iakoubov LZ, Torchilin VP (1997) A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice. Oncol Res 9: 439–446
Iakoubov LZ, Torchilin VP (1998) Nucleosome-releasing treatment makes surviving tumor cells better targets for nucleosome-specific anticancer antibodies. Cancer Detect Prev 22:470–475
Iinuma H, Maruyama K, Okinaga K, Sasaki K, Sekine T, Ishida O, Ogiwara N, Johkura K, Yonemura Y (2002) Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer 99:130–137
Imura Y, Stassen JM, Kurokawa T, Iwasa S, Lijnen HR, Collen D (1992) Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. Blood 79:2322–2329
Ishida O, Maruyama K, Tanahashi H, Iwatsuru M, Sasaki K, Eriguchi M, Yanagie H (2001) Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm Res 18:1042–1048
Ishida T, Iden DL, Allen TM (1999) A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett 460:129–133
Jain RK (1999) Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1:241–263
Jeong JH, Kim SW, Park TG (2003) Novel intracellular delivery system of antisense oligonucleotide by self-assembled hybrid micelles composed of DNA/PEG conjugate and cationic fusogenic peptide. Bioconjug Chem 14:473–479
Jeong YI, Cheon JB, Kim SH, Nah JW, Lee YM, Sung YK, Akaike T, Cho CS (1998) Clonazepam release from core-shell type nanoparticles in vitro. J Control Release 51:169–178
Johnston SR, Gore ME (2001) Caelyx: phase II studies in ovarian cancer. Eur J Cancer 37(Suppl 9):S8–S14
Jones M, Leroux J (1999) Polymeric micelles – a new generation of colloidal drug carriers. Eur J Pharm Biopharm 48:101–111
Jones MC, Ranger M, Leroux JC (2003) pH-sensitive unimolecular polymeric micelles: synthesis of a novel drug carrier. Bioconjug Chem 14:774–781
Joshee N, Bastola DR, Cheng PW (2002) Transferrin-facilitated lipofection gene delivery strategy: characterization of the transfection complexes and intracellular trafficking. Hum Gene Ther 13:1991–2004
Jule E, Nagasaki Y, Kataoka K (2003) Lactose-installed poly(ethylene glycol)-poly(d,l-lactide) block copolymer micelles exhibit fast-rate binding and high affinity toward a protein bed simulating a cell surface. A surface plasmon resonance study. Bioconjug Chem 14:177–186
Kabanov AV, Batrakova EV, Alakhov VY (2002a) Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 82:189–212
Kabanov AV, Batrakova EV, Melik-Nubarov NS, Fedoseev NA, Dorodnich TY, Alakhov VY, Chekhonin VP, Nazarova IR, Kabanov VA (1992) A new class of drug carriers: micelles of poly(oxyethylene)-poly(oxypropylene) block copolymer as microcontainers for drug targeting from blood in brain. J Control Release 22:141–157
Kabanov AV, Chekhonin VP, Alakhov V, Batrakova EV, Lebedev AS, Melik-Nubarov NS, Arzhakov SA, Levashov AV, Morozov GV, Severin ES et al (1989) The neuroleptic activity of haloperidol increases after its solubilization in surfactant micelles. Micelles as microcontainers for drug targeting. FEBS Lett 258:343–345
Kabanov AV, Lemieux P, Vinogradov S, Alakhov V (2002b) Pluronic block copolymers: novel functional molecules for gene therapy. Adv Drug Deliv Rev 54:223–233
Kakizawa Y, Kataoka K (2002) Block copolymer micelles for delivery of gene and related compounds. Adv Drug Deliv Rev 54:203–222
Kale AA, Torchilin VP (2007) Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the pH stability of PEG-PE conjugates. Bioconjug Chem 18:363–370
Kamps JA, Koning GA, Velinova MJ, Morselt HW, Wilkens M, Gorter A, Donga J, Scherphof GL (2000) Uptake of long-circulating immunoliposomes, directed against colon adenocarcinoma cells, by liver metastases of colon cancer. J Drug Target 8:235–245
Kamps JA, Scherphof GL (1998) Receptor versus non-receptor mediated clearance of liposomes. Adv Drug Deliv Rev 32:81–97
Kang N, Perron ME, Prud'homme RE, Zhang Y, Gaucher G, Leroux JC (2005) Stereocomplex block copolymer micelles: core-shell nanostructures with enhanced stability. Nano Lett 5:315–319
Katayose S, Kataoka K (1998) Remarkable increase in nuclease resistance of plasmid DNA through supramolecular assembly with poly(ethylene glycol)-poly(L-lysine) block copolymer. J Pharm Sci 87:160–163
Khaw BA (2002) Targeting the pathological myocardium. In: Muzykantov V, Torchilin VP (eds) Biomedical aspects of drug targeting. Kluwer, Dordrecht, pp 47–67
Khaw BA, daSilva J, Vural I, Narula J, Torchilin VP (2001) Intracytoplasmic gene delivery for in vitro transfection with cytoskeleton-specific immunoliposomes. J Control Release 75:199–210
Khaw BA, Torchilin VP, Vural I, Narula J (1995) Plug and seal: prevention of hypoxic cardiocyte death by sealing membrane lesions with antimyosin-liposomes. Nat Med 1:1195–1198
Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, Kim NK, Bang YJ (2004) Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10:3708–3716
Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D (1997) Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 36:66–75
Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW (2006) Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66:6732–6740
Klibanov AL, Maruyama K, Beckerleg AM, Torchilin VP, Huang L (1991) Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim Biophys Acta 1062:142–148
Klibanov AL, Maruyama K, Torchilin VP, Huang L (1990) Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 268:235–237
Klibanov AL, Muzykantov VR, Ivanov NN, Torchilin VP (1985) Evaluation of quantitative parameters of the interaction of antibody-bearing liposomes with target antigens. Anal Biochem 150:251–257
Klibanov AL, Torchilin VP, Zalipsky S (2003) Long-circulating sterically protected liposomes. In: Torchilin VP, Weissig V (eds) Liposomes: a practical approach, 2nd edn. Oxford; New York, Oxford University Press, pp 231–265
Kohori F, Sakai K, Aoyagi T, Yokoyama M, Sakurai Y, Okano T (1998) Preparation and characterization of thermally responsive block copolymer micelles comprising poly(N-isopropylacrylamide-b-DL-lactide). J Control Release 55:87–98
Koning GA, Kamps JA, Scherphof GL (2002) Efficient intracellular delivery of 5-fluorodeoxyuridine into colon cancer cells by targeted immunoliposomes. Cancer Detect Prev 26:299–307
Koning GA, Morselt HW, Velinova MJ, Donga J, Gorter A, Allen TM, Zalipsky S, Kamps JA, Scherphof GL (1999) Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells. Biochim Biophys Acta 1420:153–167
Kontermann RE (2006) Immunoliposomes for cancer therapy. Curr Opin Mol Ther 8:39–45
Kratz F, Beyer U, Schutte MT (1999) Drug-polymer conjugates containing acid-cleavable bonds. Crit Rev Ther Drug Carrier Syst 16:245–288
Kubota T, Yamamoto T, Takahara T, Furukawa T, Ishibiki K, Kitajima M, Shida Y, Nakatsubo H (1992) Targeting cancer chemotherapy using a monoclonal antibody (NCC-LU-243) conjugated with mitomycin C. J Surg Oncol 51:75–80
Kung VT, Redemann CT (1986) Synthesis of carboxyacyl derivatives of phosphatidylethanolamine and use as an efficient method for conjugation of protein to liposomes. Biochim Biophys Acta 862:435–439
Kwon GS (1998) Diblock copolymer nanoparticles for drug delivery. Crit Rev Ther Drug Carrier Syst 15:481–512
Kwon GS (2003) Polymeric micelles for delivery of poorly water-soluble compounds. Crit Rev Ther Drug Carrier Syst 20:357–403
Kwon GS, Kataoka K (1995) Block copolymer micelles as long-circulating drug vehicles. Adv Drug Deliv Rev 16:295–309
Kwon GS, Kataoka K (1999) Block copolymer micelles as long-circulating drug vehicles. Adv Drug Delivery Rev 16:295–309
Kwon GS, Okano T (1999) Soluble self-assembled block copolymers for drug delivery. Pharm Res 16:597–600
La SB, Okano T, Kataoka K (1996) Preparation and characterization of the micelle-forming polymeric drug indomethacin-incorporated poly(ethylene oxide)-poly(beta-benzyl L-aspartate) block copolymer micelles. J Pharm Sci 85:85–90
Lasic DD (1992) Mixed micelles in drug delivery. Nature 355:279–280
Lasic DD, Barenholz Y (1996) Handbook of nonmedical applications of liposomes. CRC Press, Boca Raton
Lasic DD, Martin FJ (1995) Stealth liposomes. CRC Press, Boca Raton, p 320
Lasic DD, Martin FJ, Gabizon A, Huang SK, Papahadjopoulos D (1991a) Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1070:187–192
Lasic DD, Papahadjopoulos D (1998) Medical applications of liposomes. Elsevier, Amsterdam, New York, p 779
Lasic DD, Woodle MC, Martin FJ, Valentincic T (1991b) Phase behavior of “stealth-lipid” decithin mixtures. Period Biol 93:287–290
Lavasanifar A, Samuel J, Kwon GS (2002) The effect of fatty acid substitution on the in vitro release of amphotericin B from micelles composed of poly(ethylene oxide)-block-poly(N-hexyl stearate-L-aspartamide). J Control Release 79:165–172
Le Garrec D, Taillefer J, Van Lier JE, Lenaerts V, Leroux JC (2002) Optimizing pH-responsive polymeric micelles for drug delivery in a cancer photodynamic therapy model. J Drug Target 10:429–437
Leamon CP, Cooper SR, Hardee GE (2003) Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug Chem 14:738–747
Leamon CP, Low PS (1991) Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci USA 88:5572–5576
Leamon CP, Low PS (2001) Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discov Today 6:44–51
Lee CM, Tanaka T, Murai T, Kondo M, Kimura J, Su W, Kitagawa T, Ito T, Matsuda H, Miyasaka M (2002) Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res 62:4282–4288
Lee ES, Na K, Bae YH (2003a) Polymeric micelle for tumor pH and folate-mediated targeting. J Control Release 91:103–113
Lee ES, Na K, Bae YH (2005) Super pH-sensitive multifunctional polymeric micelle. Nano Lett 5:325–329
Lee ES, Shin HJ, Na K, Bae YH (2003b) Poly(L-histidine)-PEG block copolymer micelles and pH-induced destabilization. J Control Release 90:363–374
Lee RJ, Low PS (1994) Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem 269:3198–3204
Leroux J, Roux E, Le Garrec D, Hong K, Drummond DC (2001) N-isopropylacrylamide copolymers for the preparation of pH-sensitive liposomes and polymeric micelles. J Control Release 72:71–84
Leserman LD, Barbet J, Kourilsky F, Weinstein JN (1980) Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A. Nature 288:602–604
Lestini BJ, Sagnella SM, Xu Z, Shive MS, Richter NJ, Jayaseharan J, Case AJ, Kottke-Marchant K, Anderson JM, Marchant RE (2002) Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. J Control Release 78:235–247
Levchenko TS, Rammohan R, Lukyanov AN, Whiteman KR, Torchilin VP (2002) Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm 240:95–102
Liu D, Mori A, Huang L (1991) Large liposomes containing ganglioside GM1 accumulate effectively in spleen. Biochim Biophys Acta 1066:159–165
Liu D, Mori A, Huang L (1992) Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim Biophys Acta 1104:95–101
Lopes de Menezes DE, Pilarski LM, Allen TM (1998) In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 58:3320–3330
Lu Y, Low PS (2002a) Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 54:675–693
Lu Y, Low PS (2002b) Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol Immunother 51:153–162
Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP (2004a) Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release 100:135–144
Lukyanov AN, Gao Z, Mazzola L, Torchilin VP (2002) Polyethylene glycol-diacyllipid micelles demonstrate increased acculumation in subcutaneous tumors in mice. Pharm Res 19:1424–1429
Lukyanov AN, Hartner WC, Torchilin VP (2004b) Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits. J Control Release 94:187–193
Lukyanov AN, Torchilin VP (2004) Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev 56:1273–1289
Lundberg BB, Griffiths G, Hansen HJ (2007) Cellular association and cytotoxicity of doxorubicin-loaded immunoliposomes targeted via Fab' fragments of an anti-CD74 antibody. Drug Deliv 14:171–175
Madden TD, Bally MB, Hope MJ, Cullis PR, Schieren HP, Janoff AS (1985) Protection of large unilamellar vesicles by trehalose during dehydration: retention of vesicle contents. Biochim Biophys Acta 817:67–74
Maeda H (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41:189–207
Maeda H (2003) Enhanced permeability and retention (EPR) effect: basis for drug targeting to tumors. In: Muzykantov V, Torchilin VP (eds) Biomedical aspects of drug targeting. Kluwer, Dordrecht, pp 211–228
Maeda H, Sawa T, Konno T (2001) Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 74:47–61
Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–284
Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW (2003) Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res 63:3154–3161
Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW (2005) Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 65:11631–11638
Mamot C, Ritschard R, Kung W, Park JW, Herrmann R, Rochlitz CF (2006) EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells. J Drug Target 14:215–223
Martin FJ, Papahadjopoulos D (1982) Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting. J Biol Chem 257:286–288
Marty C, Schwendener RA (2005) Cytotoxic tumor targeting with scFv antibody-modified liposomes. Methods Mol Med 109:389–402
Maruyama K, Okuizumi S, Ishida O, Yamauchi H, Kikuchi H, Iwatsuru M (1994) Phosphatidyl polyglycerols prolong liposome circulation in vivo. Int J Pharm 111:103–107
Maruyama K, Takahashi N, Tagawa T, Nagaike K, Iwatsuru M (1997) Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett 413:177–180
Maruyama K, Takizawa T, Yuda T, Kennel SJ, Huang L, Iwatsuru M (1995) Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim Biophys Acta 1234:74–80
Maruyama K, Yuda T, Okamoto A, Ishikura C, Kojima S, Iwatsuru M (1991) Effect of molecular weight in amphipathic polyethyleneglycol on prolonging the circulation time of large unilamellar liposomes. Chem Pharm Bull (Tokyo) 39:1620–1622
Maruyama K, Yuda T, Okamoto A, Kojima S, Suginaka A, Iwatsuru M (1992) Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). Biochim Biophys Acta 1128:44–49
Mastrobattista E, Koning GA, van Bloois L, Filipe AC, Jiskoot W, Storm G (2002) Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. J Biol Chem 277:27135–27143
Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, Shirao K, Okusaka T, Ueno H, Ikeda M, Watanabe N (2004) Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 91:1775–1781
Mayhew EG, Lasic D, Babbar S, Martin FJ (1992) Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. Int J Cancer 51:302–309
McBain SC, Yiu HH, Dobson J (2008) Magnetic nanoparticles for gene and drug delivery. Int J Nanomedicine 3:169–180
Metselaar JM, Bruin P, de Boer LW, de Vringer T, Snel C, Oussoren C, Wauben MH, Crommelin DJ, Storm G, Hennink WE (2003) A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. Bioconjug Chem 14:1156–1164
Meyer O, Papahadjopoulos D, Leroux JC (1998) Copolymers of N-isopropylacrylamide can trigger pH sensitivity to stable liposomes. FEBS Lett 421:61–64
Miller DW, Batrakova EV, Waltner TO, Alakhov V, Kabanov AV (1997) Interactions of pluronic block copolymers with brain microvessel endothelial cells: evidence of two potential pathways for drug absorption. Bioconjug Chem 8:649–657
Mittal KL, Lindman B (1991) Surfactants in solution, vol 1–3. Plenum Press, New York
Moein Moghimi S, Hamad I, Bunger R, Andresen TL, Jorgensen K, Hunter AC, Baranji L, Rosivall L, Szebeni J (2006) Activation of the human complement system by cholesterol-rich and PEGylated liposomes-modulation of cholesterol-rich liposome-mediated complement activation by elevated serum LDL and HDL levels. J Liposome Res 16:167–174
Moghimi SM, Szebeni J (2003) Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42:463–478
Molyneux P (1984) Water-soluble synthetic polymers: properties and behavior. CRC Press, Boca Raton
Moreira JN, Gaspar R, Allen TM (2001) Targeting Stealth liposomes in a murine model of human small cell lung cancer. Biochim Biophys Acta 1515:167–176
Moreira JN, Ishida T, Gaspar R, Allen TM (2002) Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity. Pharm Res 19:265–269
Müller RH (1991) Colloidal carriers for controlled drug delivery and targeting: modification, characterization, and in vivo distribution. CRC Press, Stuttgart, Boca Raton, Wissenschaftliche Verlagsgesellschaft
Muzykantov VR, Torchilin V (2003) Biomedical aspects of drug targeting. Kluwer, Dordrecht
Nagasaki Y, Yasugi K, Yamamoto Y, Harada A, Kataoka K (2001) Sugar-installed block copolymer micelles: their preparation and specific interaction with lectin molecules. Biomacromolecules 2:1067–1070
Naper DH (1983) Polymeric stabilization of colloidal dispersions. Academic Press, New York
Needham D, McIntosh TJ, Lasic DD (1992) Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. Biochim Biophys Acta 1108:40–48
Ni S, Stephenson SM, Lee RJ (2002) Folate receptor targeted delivery of liposomal daunorubicin into tumor cells. Anticancer Res 22:2131–2135
Niedermann G, Weissig V, Sternberg B, Lasch J (1991) Carboxyacyl derivatives of cardiolipin as four-tailed hydrophobic anchors for the covalent coupling of hydrophilic proteins to liposomes. Biochim Biophys Acta 1070:401–408
Nobs L, Buchegger F, Gurny R, Allemann E (2004) Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci 93:1980–1992
O'Shaughnessy JA (2003) Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin Breast Cancer 4:318–328
Ogris M, Brunner S, Schuller S, Kircheis R, Wagner E (1999) PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther 6:595–605
Omori N, Maruyama K, Jin G, Li F, Wang SJ, Hamakawa Y, Sato K, Nagano I, Shoji M, Abe K (2003) Targeting of post-ischemic cerebral endothelium in rat by liposomes bearing polyethylene glycol-coupled transferrin. Neurol Res 25:275–279
Orekhova NM, Akchurin RS, Belyaev AA, Smirnov MD, Ragimov SE, Orekhov AN (1990) Local prevention of thrombosis in animal arteries by means of magnetic targeting of aspirin-loaded red cells. Thromb Res 57:611–616
Ota T, Maeda M, Tatsuka M (2002) Cationic liposomes with plasmid DNA influence cancer metastatic capability. Anticancer Res 22:4049–4052
Otsuka H, Nagasaki Y, Kataoka K (2003) PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev 55:403–419
Palmer TN, Caride VJ, Caldecourt MA, Twickler J, Abdullah V (1984) The mechanism of liposome accumulation in infarction. Biochim Biophys Acta 797:363–368
Pan H, Han L, Chen W, Yao M, Lu W (2008) Targeting to tumor necrotic regions with biotinylated antibody and streptavidin modified liposomes. J Control Release 125:228–235
Pan X, Lee RJ (2007) Construction of anti-EGFR immunoliposomes via folate-folate binding protein affinity. Int J Pharm 336:276–283
Pan X, Wu G, Yang W, Barth RF, Tjarks W, Lee RJ (2007) Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR. Bioconjug Chem 18:101–108
Pan XQ, Wang H, Lee RJ (2003) Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm Res 20:417–422
Pan XQ, Zheng X, Shi G, Wang H, Ratnam M, Lee RJ (2002) Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 100:594–602
Pang SNJ (1993) Final report on the safety assessment of polyethylene glycols (PEGs) -6, -8, -32, -75, -150, -14M, -20M. J Am Coll Toxicol 12:429–457
Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C et al (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88:11460–11464
Park EK, Kim SY, Lee SB, Lee YM (2005) Folate-conjugated methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric micelles for tumor-targeted drug delivery. J Control Release 109:158–168
Park JW, Benz CC, Martin FJ (2004) Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 31:196–205
Park JW, Hong K, Carter P, Asgari H, Guo LY, Keller GA, Wirth C, Shalaby R, Kotts C, Wood WI et al (1995) Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA 92:1327–1331
Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC (2002) Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8:1172–1181
Park JW, Hong K, Kirpotin DB, Meyer O, Papahadjopoulos D, Benz CC (1997) Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett 118:153–160
Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC (2001) Tumor targeting using anti-her2 immunoliposomes. J Control Release 74:95–113
Pastorino F, Brignole C, Di Paolo D, Nico B, Pezzolo A, Marimpietri D, Pagnan G, Piccardi F, Cilli M, Longhi R, Ribatti D, Corti A, Allen TM, Ponzoni M (2006) Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 66:10073–10082
Pastorino F, Brignole C, Marimpietri D, Sapra P, Moase EH, Allen TM, Ponzoni M (2003) Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 63:86–92
Pauwels EK, Erba P (2007) Towards the use of nanoparticles in cancer therapy and imaging. Drug News Perspect 20:213–220
Peer D, Margalit R (2004) Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer 108:780–789
Perez-Lopez ME, Curiel T, Gomez JG, Jorge M (2007) Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer. Anticancer Drugs 18:611–617
Perez AT, Domenech GH, Frankel C, Vogel CL (2002) Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc. experience. Cancer Invest (Suppl 2) 20:22–29
Potineni A, Lynn DM, Langer R, Amiji MM (2003) Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive biodegradable system for paclitaxel delivery. J Control Release 86:223–234
Powell GM (1980) Polyethylene glycol. In: Davidson RL (ed) Handbook of water-soluble gums and resins. McGraw-Hill, New York, pp 1–31
Qin J, Chen D, Hu H, Cui Q, Qiao M, Chen B (2007) Surface modification of RGD-liposomes for selective drug delivery to monocytes/neutrophils in brain. Chem Pharm Bull (Tokyo) 55:1192–1197
Raffaghello L, Pagnan G, Pastorino F, Cosimo E, Brignole C, Marimpietri D, Bogenmann E, Ponzoni M, Montaldo PG (2003) Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma. Cancer Lett 197:151–155
Rammohan R, Levchenko T, Weissig V, Chakilam A, Torchilin V (2001) Immunomicelles: attachment of specific ligands including monoclonal antibodies to polymeric micelles. 28th International Symposium on Controlled Release of Bioactive Materials, San Diego 2001. Control Release Society, Inc., pp 484–485
Reddy JA, Abburi C, Hofland H, Howard SJ, Vlahov I, Wils P, Leamon CP (2002) Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther 9:1542–1550
Ringsdorf H (1975) Structure and properties of pharmacologically active polymers. J Polym Sci 51:135–153
Rolland A (1993) Pharmaceutical particulate carriers: therapeutic applications carriers. Marcel Dekker, New York
Rose PG (2005) Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 10:205–214
Roth A, Drummond DC, Conrad F, Hayes ME, Kirpotin DB, Benz CC, Marks JD, Liu B (2007) Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther 6:2737–2746
Roux E, Francis M, Winnik FM, Leroux JC (2002a) Polymer based pH-sensitive carriers as a means to improve the cytoplasmic delivery of drugs. Int J Pharm 242:25–36
Roux E, Passirani C, Scheffold S, Benoit JP, Leroux JC (2004) Serum-stable and long-circulating, PEGylated, pH-sensitive liposomes. J Control Release 94:447–451
Roux E, Stomp R, Giasson S, Pezolet M, Moreau P, Leroux JC (2002b) Steric stabilization of liposomes by pH-responsive N-isopropylacrylamide copolymer. J Pharm Sci 91:1795–1802
Rowe RC, Sheskey PJ, Weller PJ (2003) Handbook of pharmaceutical excipients, 4th edn. Pharmaceutical Press, American Pharmaceutical Association, London, Chicago Washington, DC
Sapra P, Allen TM (2003) Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 42: 439–462
Sapra P, Allen TM (2004) Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin Cancer Res 10:2530–2537
Sawant RM, Hurley JP, Salmaso S, Kale A, Tolcheva E, Levchenko TS, Torchilin VP (2006) “SMART” drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem 17:943–949
Schiffelers RM, Koning GA, ten Hagen TL, Fens MH, Schraa AJ, Janssen AP, Kok RJ, Molema G, Storm G (2003) Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release 91:115–122
Schmidinger M, Wenzel C, Locker GJ, Muehlbacher F, Steininger R, Gnant M, Crevenna R, Budinsky AC (2001) Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. Br J Cancer 85:1850–1852
Schnyder A, Krahenbuhl S, Drewe J, Huwyler J (2005) Targeting of daunomycin using biotinylated immunoliposomes: pharmacokinetics, tissue distribution and in vitro pharmacological effects. J Drug Target 13:325–335
Schwonzen M, Kurbacher CM, Mallmann P (2000) Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. Anticancer Drugs 11:681–685
Senior J, Delgado C, Fisher D, Tilcock C, Gregoriadis G (1991) Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim Biophys Acta 1062:77–82
Senior JH (1987) Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 3:123–193
Shalaev EY, Steponkus PL (1999) Phase diagram of 1, 2-dioleoylphosphatidylethanolamine (DOPE): water system at subzero temperatures and at low water contents. Biochim Biophys Acta 1419:229–247
Sheff D (2004) Endosomes as a route for drug delivery in the real world. Adv Drug Deliv Rev 56:927–930
Shuai X, Merdan T, Schaper AK, Xi F, Kissel T (2004) Core-cross-linked polymeric micelles as paclitaxel carriers. Bioconjug Chem 15:441–448
Simoes S, Moreira JN, Fonseca C, Duzgunes N, de Lima MC (2004) On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev 56:947–965
Skubitz KM (2003) Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest 21:167–176
Sofou S, Sgouros G (2008) Antibody-targeted liposomes in cancer therapy and imaging. Expert Opin Drug Deliv 5:189–204
Sou K, Endo T, Takeoka S, Tsuchida E (2000) Poly(ethylene glycol)-modification of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles. Bioconjug Chem 11:372–379
Stephenson SM, Yang W, Stevens PJ, Tjarks W, Barth RF, Lee RJ (2003) Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy. Anticancer Res 23:3341–3345
Sudimack JJ, Guo W, Tjarks W, Lee RJ (2002) A novel pH-sensitive liposome formulation containing oleyl alcohol. Biochim Biophys Acta 1564:31–37
Sugano M, Egilmez NK, Yokota SJ, Chen FA, Harding J, Huang SK, Bankert RB (2000) Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res 60:6942–6949
Sun C, Lee JS, Zhang M (2008) Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 60:1252–1265
Suzawa T, Nagamura S, Saito H, Ohta S, Hanai N, Kanazawa J, Okabe M, Yamasaki M (2002) Enhanced tumor cell selectivity of adriamycin-monoclonal antibody conjugate via a poly(ethylene glycol)-based cleavable linker. J Control Release 79:229–242
Symon Z, Peyser A, Tzemach D, Lyass O, Sucher E, Shezen E, Gabizon A (1999) Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 86:72–78
Szoka F Jr, Papahadjopoulos D (1980) Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng 9:467–508
Takeuchi H, Kojima H, Toyoda T, Yamamoto H, Hino T, Kawashima Y (1999) Prolonged circulation time of doxorubicin-loaded liposomes coated with a modified polyvinyl alcohol after intravenous injection in rats. Eur J Pharm Biopharm 48:123–129
Takeuchi H, Kojima H, Yamamoto H, Kawashima Y (2001) Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. J Control Release 75:83–91
Tan PH, Manunta M, Ardjomand N, Xue SA, Larkin DF, Haskard DO, Taylor KM, George AJ (2003) Antibody targeted gene transfer to endothelium. J Gene Med 5:311–323
Terada T, Mizobata M, Kawakami S, Yamashita F, Hashida M (2007) Optimization of tumor-selective targeting by basic fibroblast growth factor-binding peptide grafted PEGylated liposomes. J Control Release 119:262–270
Torchilin V, Klibanov A (1993) Coupling and labeling of phospholipids. In: Cevc G (ed) Phospholipid Handbook. Marcel Dekker, New York, pp 293–322
Torchilin VP (1991) Immobilized enzymes in medicine. Progress in clinical biochemistry and medicine Vol 11. Springer, Berlin, p 206
Torchilin VP (1995) Handbook of targeted delivery of imaging agents. CRC Press, Boca Raton, FL
Torchilin VP (1996a) Affinity liposomes in vivo: factors influencing target accumulation. J Mol Recognit 9:335–346
Torchilin VP (1996b) How do polymers prolong circulation times of liposomes. J Liposome Res 9:99–116
Torchilin VP (1998) Polymer-coated long-circulating microparticulate pharmaceuticals. J Microencapsul 15:1–19
Torchilin VP (2000) Drug targeting. Eur J Pharm Sci 11(Suppl 2):S81–S91
Torchilin VP (2001) Structure and design of polymeric surfactant-based drug delivery systems. J Control Release 73:137–172
Torchilin VP (2002) Strategies and means for drug targeting: an overview. In: Muzykantov V, Torchilin VP (eds) Biomedical aspects of drug targeting. Kluwer, Boston, pp 3–26
Torchilin VP (2008) Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 60:548–558
Torchilin VP, Klibanov AL, Huang L, O'Donnell S, Nossiff ND, Khaw BA (1992) Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. FASEB J 6:2716–2719
Torchilin VP, Klibanov AL, Ivanov NN, Gluckhova MA, Koteliansky VE, Kleinman HK, Martin GR (1985) Binding of antibodies in liposomes to extracellular matrix antigens. J Cell Biochem 28:23–29
Torchilin VP, Levchenko TS (2003) TAT-liposomes: a novel intracellular drug carrier. Curr Protein Pept Sci 4:133–140
Torchilin VP, Levchenko TS, Lukyanov AN, Khaw BA, Klibanov AL, Rammohan R, Samokhin GP, Whiteman KR (2001a) p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim Biophys Acta 1511:397–411
Torchilin VP, Levchenko TS, Rammohan R, Volodina N, Papahadjopoulos-Sternberg B, D'Souza GG (2003a) Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci USA 100:1972–1977
Torchilin VP, Levchenko TS, Whiteman KR, Yaroslavov AA, Tsatsakis AM, Rizos AK, Michailova EV, Shtilman MI (2001b) Amphiphilic poly-N-vinylpyrrolidones: synthesis, properties and liposome surface modification. Biomaterials 22:3035–3044
Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B (2003b) Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci USA 100:6039–6044
Torchilin VP, Omelyanenko VG, Papisov MI, Bogdanov AA Jr, Trubetskoy VS, Herron JN, Gentry CA (1994) Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim Biophys Acta 1195:11–20
Torchilin VP, Papisov MI, Orekhova NM, Belyaev AA, Petrov AD, Ragimov SE (1988) Magnetically driven thrombolytic preparation containing immobilized streptokinase-targeted transport and action. Haemostasis 18:113–116
Torchilin VP, Trubetskoy VS (1995) Which polymers can make nanoparticulate drug carriers long-circulating? Adv Drug Deliv Rev 16:141–155
Torchilin VP, Trubetskoy VS, Whiteman KR, Caliceti P, Ferruti P, Veronese FM (1995) New synthetic amphiphilic polymers for steric protection of liposomes in vivo. J Pharm Sci 84:1049–1053
Torchilin VP, Weissig V (2003) Liposomes: a practical approach. Practical approach series, Vol 264, 2nd edn. Oxford University Press, Oxford, p 396
Torchilin VP, Weissig V, Martin FJ, Heath TD, New RRC (2003c) Surface modifications of liposomes. In: Torchilin VP, Weissig V (eds) Liposomes: a practical approach, 2nd edn. Oxford University Press, Oxford, pp 193–229
Torchilin VP, Zhou F, Huang L (1993) pH-sensitive liposomes. J Liposome Res 3:201–255
Trubetskaya OV, Trubetskoy VS, Domogatsky SP, Rudin AV, Popov NV, Danilov SM, Nikolayeva MN, Klibanov AL, Torchilin VP (1988) Monoclonal antibody to human endothelial cell surface internalization and liposome delivery in cell culture. FEBS Lett 228:131–134
Trubetskoy VS, Gazelle GS, Wolf GL, Torchilin VP (1997) Block-copolymer of polyethylene glycol and polylysine as a carrier of organic iodine: design of long-circulating particulate contrast medium for X-ray computed tomography. J Drug Target 4:381–388
Trubetskoy VS, Torchilin VP (1995) Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents. Adv Drug Deliv Rev 16:311–320
Tuffin G, Waelti E, Huwyler J, Hammer C, Marti HP (2005) Immunoliposome targeting to mesangial cells: a promising strategy for specific drug delivery to the kidney. J Am Soc Nephrol 16:3295–3305
Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, Nishiyama N, Kataoka K, Naito S, Kakizoe T (2005) Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer 93:678–687
Varga CM, Wickham TJ, Lauffenburger DA (2000) Receptor-mediated targeting of gene delivery vectors: insights from molecular mechanisms for improved vehicle design. Biotechnol Bioeng 70:593–605
Venugopalan P, Jain S, Sankar S, Singh P, Rawat A, Vyas SP (2002) pH-sensitive liposomes: mechanism of triggered release to drug and gene delivery prospects. Pharmazie 57:659–671
Veronese FM (2001) Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 22:405–417
Vingerhoeds MH, Storm G, Crommelin DJ (1994) Immunoliposomes in vivo. Immunomethods 4:259–272
Vinogradov S, Batrakova E, Li S, Kabanov A (1999) Polyion complex micelles with protein-modified corona for receptor-mediated delivery of oligonucleotides into cells. Bioconjug Chem 10:851–860
Vinogradov SV, Bronich TK, Kabanov AV (1998) Self-assembly of polyamine-poly(ethylene glycol) copolymers with phosphorothioate oligonucleotides. Bioconjug Chem 9:805–812
Vitetta ES, Krolick KA, Miyama-Inaba M, Cushley W, Uhr JW (1983) Immunotoxins: a new approach to cancer therapy. Science 219:644–650
Voinea M, Manduteanu I, Dragomir E, Capraru M, Simionescu M (2005) Immunoliposomes directed toward VCAM-1 interact specifically with activated endothelial cells–a potential tool for specific drug delivery. Pharm Res 22:1906–1917
Volkel T, Holig P, Merdan T, Muller R, Kontermann RE (2004) Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim Biophys Acta 1663:158–166
Vutla NB, Betageri GV, Banga AK (1996) Transdermal iontophoretic delivery of enkephalin formulated in liposomes. J Pharm Sci 85:5–8
Wakebayashi D, Nishiyama N, Yamasaki Y, Itaka K, Kanayama N, Harada A, Nagasaki Y, Kataoka K (2004) Lactose-conjugated polyion complex micelles incorporating plasmid DNA as a targetable gene vector system: their preparation and gene transfecting efficiency against cultured HepG2 cells. J Control Release 95:653–664
Wang GP, Qi ZH, Chen FP (2008) Treatment of acute myeloid leukemia by directly targeting both leukemia stem cells and oncogenic molecule with specific scFv-immunolipoplexes as a deliverer. Med Hypotheses 70:122–127
Wang J, Mongayt D, Torchilin VP (2005) Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. J Drug Target 13:73–80
Weinstein JN, Magin RL, Yatvin MB, Zaharko DS (1979) Liposomes and local hyperthermia: selective delivery of methotrexate to heated tumors. Science 204:188–191
Weissig V, Gregoriadis G (1992) Coupling of aminogroup bearing ligands to liposomes. In: Gregoriadis G (ed) Liposome technology, vol 3. CRC Press, Boca Raton, pp 231–248
Weissig V, Lasch J, Gregoriadis G (1990) Covalent binding of peptides at liposome surfaces. Pharmazie 45:849–850
Weissig V, Lasch J, Klibanov AL, Torchilin VP (1986) A new hydrophobic anchor for the attachment of proteins to liposomal membranes. FEBS Lett 202:86–90
Weissig V, Whiteman KR, Torchilin VP (1998) Accumulation of protein-loaded long-circulating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice. Pharm Res 15:1552–1556
Whiteman KR, Subr V, Ulbrich K, Torchilin VP (2001) Poly(HPMA)-coated liposomes demonstrate prolonged circulation in mice. J Liposome Res 11:153–164
Widder KJ, Marino PA, Morris RM, Senyei AE (1983) Targeting antineoplastic agents using magnetic albumin microspheres. In: Goldberg EP (ed) Targeted Drugs. Wiley, New York, pp 201–230
Williams AS, Camilleri JP, Goodfellow RM, Williams BD (1996) A single intra-articular injection of liposomally conjugated methotrexate suppresses joint inflammation in rat antigen-induced arthritis. Br J Rheumatol 35:719–724
Winslow RM, Vandegriff KD, Intaglietta M (1996) Blood substitutes: new challenges. Birkhäuser, Boston
Wollina U, Dummer R, Brockmeyer NH, Konrad H, Busch JO, Kaatz M, Knopf B, Koch HJ, Hauschild A (2003) Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98:993–1001
Woodle MC (1993) Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation. Chem Phys Lipids 64:249–262
Woodle MC (1998) Controlling liposome blood clearance by surface-grafted polymers. Adv Drug Deliv Rev 32:139–152
Woodle MC, Engbers CM, Zalipsky S (1994) New amphipatic polymer-lipid conjugates forming long-circulating reticuloendothelial system-evading liposomes. Bioconjug Chem 5:493–496
Woodle MC, Storm G (1998) Long circulating liposomes: old drugs, new therapeutics. Biotechnology intelligence unit. Springer, Berlin, p 301
Xiong XB, Mahmud A, Uludag H, Lavasanifar A (2007) Conjugation of arginine-glycine-aspartic acid peptides to poly(ethylene oxide)-b-poly(epsilon-caprolactone) micelles for enhanced intracellular drug delivery to metastatic tumor cells. Biomacromolecules 8:874–884
Xu L, Huang CC, Huang W, Tang WH, Rait A, Yin YZ, Cruz I, Xiang LM, Pirollo KF, Chang EH (2002) Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther 1:337–346
Yamaoka T, Tabata Y, Ikada Y (1994) Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci 83:601–606
Yang T, Choi MK, Cui FD, Kim JS, Chung SJ, Shim CK, Kim DD (2007) Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release 120:169–177
Yerushalmi N, Arad A, Margalit R (1994) Molecular and cellular studies of hyaluronic acid-modified liposomes as bioadhesive carriers for topical drug delivery in wound healing. Arch Biochem Biophys 313:267–273
Yoo HS, Lee EA, Park TG (2002) Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages. J Control Release 82:17–27
Yoo HS, Park TG (2004) Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J Control Release 100:247–256
Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK (1995) Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55:3752–3756
Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK (1994) Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 54:3352–3356
Yuan X, Harada A, Yamasaki Y, Kataoka K (2005) Stabilization of lysozyme-incorporated polyion complex micelles by the omega-end derivatization of poly(ethylene glycol)-poly(alpha, beta-aspartic acid) block copolymers with hydrophobic groups. Langmuir 21:2668–2674
Zalipsky S (1995) Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv Drug Deliv Rev 16:157–182
Zalipsky S, Gittelman J, Mullah N, Qazen MM, Harding JA (1998) Biologically active ligand-bearing polymer-grafted liposomes. In: Gregoriadis G (ed) Targeting of drugs 6: strategies for stealth therapeutic systems. Plenum Press, New York, pp 131–139
Zalipsky S, Qazen M, Walker JA 2nd, Mullah N, Quinn YP, Huang SK (1999) New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. Bioconjug Chem 10:703–707
Zhang JX, Zalipsky S, Mullah N, Pechar M, Allen TM (2004) Pharmaco attributes of dioleoylphosphatidylethanolamine/cholesterylhemisuccinate liposomes containing different types of cleavable lipopolymers. Pharmacol Res 49:185–198
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Torchilin, V.P. (2010). Passive and Active Drug Targeting: Drug Delivery to Tumors as an Example. In: Schäfer-Korting, M. (eds) Drug Delivery. Handbook of Experimental Pharmacology, vol 197. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-00477-3_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-00477-3_1
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-00476-6
Online ISBN: 978-3-642-00477-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)